Compare Incyte Corporation (INCY) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Rockwell Automation — how do they compare? Incyte Corporation trades at $121.44 (market cap $24.54B), while Rockwell Automation trades at $450.31 (market cap $49.64B). The key difference: Rockwell Automation is far larger — about 2× Incyte Corporation's market cap, and Rockwell Automation pays a 1.23% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ROK | |
|---|---|---|
Market Cap | $24.54B | $49.64B |
Sector | Health | Industrials |
52-Week High | $129.93 | $495.08 |
52-Week Low | $81.61 | $333.75 |
Enterprise Value | $20.04B | $52.77B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Rockwell Automation (ROK) trades at $435.22, down 1.32% with a bearish technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and raised 2026 guidance. Valuation metrics appear elevated with P/E of 41.85 and P/S of 5.6, while profitability remains solid with 13.38% net margin. Recent AI integration initiatives and institutional buying activity provide positive catalysts.
ROK presents a mixed outlook with strong operational performance offset by premium valuation. The 16.5% upside to consensus price target of $507 offers potential, but inflation pressures and competitive threats require monitoring. Current technical weakness near support at $432 creates a critical juncture for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
